Abstract
Our findings indicated that HLA-DR<sup>+</sup>CD38<sup>hi</sup> CD8<sup>+</sup> T cells were correlated with disease severity of COVID-19 rather than HLA-DR<sup>+</sup>CD38<sup>dim</sup> population.
Introduction
Early in the COVID-19 pandemic, clinicians observed a paradoxical immune state in severe patients: a drastic reduction in total T cells (lymphopenia) alongside high activation markers (HLA-DR and CD38) on the remaining cells. This study investigates whether these activated CD8+ T cells are beneficial or detrimental, specifically by distinguishing between different intensities of CD38 expression to identify biomarkers for disease progression.
Methods and Materials
Researchers conducted a retrospective longitudinal study of 42 COVID-19 patients (32 mild/moderate, 10 severe/critical) at Beijing Ditan Hospital, compared against 20 healthy donors (HD).
- Flow Cytometry: Used to categorize T cell subsets based on HLA-DR and CD38 expression levels.
- Multiplex Assays: Measured 45 cytokines/chemokines and 14 soluble immune checkpoints.
- Transcriptional Profiling: Analyzed transcription factors (T-bet, Eomes) to assess cell exhaustion.
- Clinical Correlation: Mapped T cell percentages against markers of organ damage (LDH, AST, Creatinine) and systemic inflammation (CRP, SAA).
Key Insights: Functional Dysregulation
The study reveals a critical distinction between HLA-DR⁺CD38dim and HLA-DR⁺CD38hi CD8⁺ T cells. While the "dim" population represents a standard functional immune response, the "high" population signifies immune dysregulation.
- Exhaustion Profile: CD38hi cells exhibited higher levels of inhibitory checkpoints (PD-1, TIM-3, LAG-3) and a transcriptional profile (T-bet^dim Eomes^hi) characteristic of terminal exhaustion.
- Pro-apoptotic State: These cells showed increased expression of BAX and decreased Bcl-2, suggesting they are prone to programmed cell death, contributing to systemic lymphopenia.
- Impaired Cytotoxicity: Despite containing granzyme B and perforin, their actual "killing potential" was diminished compared to the CD38dim subset.
Results and Clinical Significance
The percentage of HLA-DR⁺CD38hi CD8⁺ T cells serves as a robust biomarker for disease severity. In severe cases, these cells peaked at approximately 23.5% of the CD8⁺ population, whereas they only reached 3.2% in mild cases.
Furthermore, the persistence of these cells was markedly different; they declined rapidly in mild cases but remained elevated for weeks in severe patients. This subset showed a strong positive correlation with Lactate Dehydrogenase (LDH) (R=0.643, P<0.0001), indicating a direct link between this overactivated immune state and physical tissue injury.
Discussion and Limitations
While these findings identify a specific cellular biomarker for severe COVID-19, the study is limited by its small sample size (n=42). Additionally, the lack of direct in vitro functional assays means the "impaired killing" is inferred from molecular markers. Future research is required to determine if these cells are a cause of tissue damage or a secondary symptom of overwhelming inflammation, potentially opening doors for targeted immunotherapies.
Summary updated